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Abstract 15 
Background & aims: Nut intake has been associated with reduced cancer-related mortality and cancer risk. 16 
However, very few studies investigated the association between nut consumption and the risk of endometrial and 17 
ovarian cancer, with inconclusive results. We prospectively examined the relation between total nut, tree nut, 18 
peanut, and peanut butter intake and the risk of endometrial and ovarian cancer in the prospective Netherlands 19 
Cohort Study (NLCS).  20 
Methods: In 1986, 62,573 women aged 55-69 years were included in the NLCS. At baseline, all participants 21 
filled in a questionnaire and a subcohort of 2,589 women was randomly selected. After 20.3 years of follow-up, 22 
389 endometrial and 347 ovarian cancer cases with complete data were included in the analysis. Hazard ratios 23 
(HRs) were calculated in multivariable-adjusted Cox regression analyses, using a case-cohort approach.  24 
Results: Compared to nonconsumers, the HRs (95% confidence intervals) for women consuming 10+ g total 25 
nuts/day were 1.23 (0.82-1.87) for endometrial cancer and 0.84 (0.57-1.24) for ovarian cancer. For tree nut, 26 
peanut, and peanut butter intake, also no significant relations with endometrial or ovarian cancer were observed. 27 
In the endometrial cancer analyses, significant interactions of total nut intake with body mass index and cigarette 28 
smoking status were found.  29 
Conclusions: The results of this study suggest that intake of total nuts, tree nuts, peanuts, and peanut butter is 30 
not related to the risk of endometrial or ovarian cancer. The observed interactions in the endometrial cancer 31 
analyses, in particular with cigarette smoking status, require confirmation in other studies. 32 
 33 
Keywords: Endometrial cancer, Ovarian cancer, Nuts, Peanut butter, Cohort studies 34 
 35 
Abbreviations: AIC, Akaike Information Criterion; aMED, alternate Mediterranean diet; BMI, body mass 36 
index; CI, confidence interval; HR, hazard ratio; NLCS, Netherlands Cohort Study; PH, proportional hazards; 37 
SD, standard deviation  38 
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Introduction 39 
In 2012, uterine corpus cancer, which predominantly comprises endometrial cancer [1], was the fourth most 40 
common cancer in women in developed countries; ovarian cancer ranked fifth [2]. The development of 41 
endometrial cancer has mainly been linked to an excess of estrogen relative to progesterone [3]. For ovarian 42 
cancer, the most common explanation is the incessant ovulation hypothesis, which suggests that reproductive 43 
tissue turnover results in an accumulation of genetic damage [3-5]. Although endometrial and ovarian cancers 44 
are two distinct entities, these hypothesized mechanisms might apply to both cancer types [3]. Other proposed 45 
mechanisms for both cancer types relate, amongst others, to inflammation, gonadotropin stimulation, and mucin-46 
related immunity [3, 5-7].  47 
Recently, increased nut consumption has been associated with reduced cancer-related mortality and cancer risk 48 
[8-15]. Several animal and human studies stated that phytoestrogens in nuts (isoflavonoids and lignans) might 49 
modify sex hormone metabolism and activity, thereby possibly reducing the risk of hormone-dependent cancers 50 
[16, 17]. Other proposed mechanisms by which nuts have been suggested to conduct their cancer-51 
chemopreventive effects relate, amongst others, to their antioxidant activity, regulation of immunological and 52 
anti-inflammatory responses, and regulation of cell proliferation and differentiation [16, 18-20]. 53 
Very few studies investigated the association between nut consumption and the risk of endometrial and ovarian 54 
cancer, with contradictive results: to our knowledge, only three case-control studies were performed for 55 
endometrial cancer [21-23], and one cohort [24] and two case-control studies for ovarian cancer [25, 26]. 56 
Because these studies are inconclusive and because prospective evidence regarding these relations is very 57 
limited, we investigated the role of tree nut, peanut, and peanut butter consumption in the development of 58 
endometrial and ovarian cancer in the prospective Netherlands Cohort Study on diet and cancer (NLCS).  59 
Materials and methods 60 
Study design and cancer follow-up 61 
The NLCS was initiated in September 1986, when 62,573 women aged 55-69 years were enrolled [27]. These 62 
women agreed to participate by filling in and returning a baseline questionnaire, which measured dietary habits 63 
and other cancer risk factors. Ethical approval of the NLCS was obtained from the institutional review boards of 64 
the Maastricht University and the Netherlands Organization for Applied Scientific Research (TNO). The NLCS 65 
was conducted in accordance with the Declaration of Helsinki. A case-cohort approach was applied to improve 66 
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the efficiency of the data processing and analysis. Following this approach, incident cases were derived from the 67 
entire cohort, whereas person-years at risk were estimated from a subcohort. This subcohort consisted of 2,589 68 
women who were randomly sampled from the total cohort directly after baseline. Subcohort members were 69 
followed up biennially for vital status information until December 2006. After 20.3 years of follow-up 70 
(September 1986 until December 2006), no subcohort members were lost to follow-up. 71 
Follow-up for cancer incidence was performed through annual record linkage with the Netherlands Cancer 72 
Registry and the Netherlands Pathology Registry (PALGA) [28]. The completeness of the cancer follow-up was 73 
estimated to be higher than 95% [29].  74 
After 20.3 years of follow-up, 551 incident endometrial and 498 incident ovarian cancer cases were detected. 75 
Prevalent cancer cases (except for skin cancer), non-epithelial or borderline invasive cases, or cases without 76 
microscopic confirmation were excluded. Participants were excluded if they had a hysterectomy (excluded from 77 
the endometrial cancer analysis) or an oophorectomy (excluded from the ovarian cancer analysis). Moreover, 78 
cases and subcohort members with incomplete or inconsistent dietary data, or with missing data on confounders 79 
were also excluded. Applying these criteria resulted in 1,452 subcohort members and 389 endometrial cancer 80 
cases for the analyses of endometrial cancer, and 1,646 subcohort members and 347 ovarian cancer cases for the 81 
analyses of ovarian cancer (Figure 1).  82 
Exposure assessment 83 
Smoking habits, physical activity, anthropometrics, dietary intakes, and other cancer risk factors were evaluated 84 
with a mailed, self-administered, 11-page baseline questionnaire. Information about habitual diet in the year 85 
preceding baseline was assessed with a validated 150-item semi-quantitative food frequency questionnaire [30]. 86 
Intake of peanuts, tree nuts, and peanut butter was estimated by asking for intake frequencies and number of 87 
standard portion sizes consumed per intake of ‘peanuts’, ‘other, mixed nuts’ (tree nuts), and ‘peanut butter’. 88 
Intake frequencies could range from ‘never or less than 1x/month’ to ‘6-7x/week’. A standard portion size was 89 
assumed 28 g for tree nuts and peanuts, and 15 g per slice of bread for peanut butter. Daily intakes were 90 
calculated by multiplying intake frequencies and portion sizes. Total nut intake was calculated as the sum of 91 
daily tree nut and peanut intake. 92 
Statistical analysis 93 
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The relation between nut and peanut butter intake and the risk of endometrial and ovarian cancer was analyzed in 94 
age- and multivariable-adjusted Cox regression analyses. The proportional hazards (PH) assumption was 95 
evaluated with Schoenfeld residuals [31], log-log survival plots, and by including time-varying covariates. No 96 
violations of this assumption were observed in the endometrial and ovarian cancer analyses for the exposure 97 
variables. In case the PH assumption was violated for confounders, time-covariate interactions for those 98 
variables were included. Standard errors were calculated with the robust Huber-White sandwich estimator to 99 
account for the additional variance introduced by the sampling from the entire cohort [32]. 100 
The relation between nut and peanut butter intake and endometrial and ovarian cancer risk was tested on a 101 
categorical and continuous scale (per 5 g/day increment). For the categorical analyses, total nut and peanut 102 
intake were divided into categories of 0, 0.1-<5, 5-<10, and 10+ g/day, and tree nut and peanut butter intake into 103 
0, 0.1-<5, and 5+ g/day, because of the lower number of cases in the higher intake categories. Linear trends were 104 
investigated by assigning median nut intake values in the subcohort to the intake categories and fitting these as a 105 
continuous variable in the regression models. 106 
In the multivariable-adjusted models, estimates were adjusted for the following predefined confounders: age 107 
(years; continuous), cigarette smoking (status (never, former, current), frequency (n/day; continuous, centered), 108 
and duration (years; continuous, centered)), body mass index (BMI; <18.5, 18.5-<25, 25-<30, ≥30 kg/m2), 109 
nonoccupational physical activity (≤30, >30-60, >60-90, >90 min/day), educational level (primary or lower 110 
vocational (low), secondary or medium vocational (medium), higher vocational or university (high)), age at 111 
menarche (years; continuous), age at menopause (years; continuous), parity and age at first child birth 112 
(nulliparous, 1-2 children - <25 years, 1-2 children - ≥25 years, ≥3 children - <25 years, ≥3 children - ≥25 years), 113 
oral contraceptive use (never, ever), hormone replacement therapy use (never, ever), daily energy intake 114 
(kcal/day; continuous), and the alternate Mediterranean diet (aMED) score excluding alcohol and nuts [33] (0-2, 115 
3-4, 5-7 points). In the endometrial cancer analyses, we additionally adjusted for family history of endometrial 116 
cancer (no, yes), and in the ovarian cancer analyses for family history of breast cancer (no, yes). Initially, we 117 
also adjusted the ovarian cancer analyses for family history of ovarian cancer. However, because only three 118 
participants reported a positive family history, this factor was excluded from the final model, which did not 119 
importantly change the estimates. We also checked the following potential confounders: intake of coffee, 120 
nutritional supplement use, history of diabetes (for the endometrial cancer analyses only), history of 121 
hypertension (for the endometrial cancer analyses only), hysterectomy (for the ovarian cancer analyses only), 122 
6 
 
and height. Because these variables did not change the estimates with minimally 10% when using a backward 123 
stepwise selection procedure, they were excluded from the final model.  124 
To further investigate the linearity of the exposure-response relation between nut and peanut butter intake and 125 
endometrial and ovarian cancer risk, we performed restricted cubic splines analyses with three fixed knots at 0, 126 
5, and 10 g intake/day. To examine the assumptions regarding the number and placement of knots, we compared 127 
the fit of several models with additional knots or different knot positions using the Akaike Information Criterion 128 
(AIC) score [34]. 129 
Potential residual confounding and interactions were investigated by stratifying the relation between total nut 130 
intake and endometrial and ovarian cancer by BMI, nonoccupational physical activity, cigarette smoking status, 131 
educational level, and aMED score excluding alcohol and nuts. For ovarian cancer, we also investigated 132 
potential interactions by family history of breast cancer (no, yes). We could not stratify by family history of 133 
endometrial cancer (in the endometrial cancer analysis) or by family history of ovarian cancer (in the ovarian 134 
cancer analysis), because of the limited number of participants with a positive family history. The total nut intake 135 
categories of 5-<10 g/day and 10+ g/day were merged to increase statistical power. Participant with a BMI <18.5 136 
kg/m2 were excluded from the analysis stratified by BMI because of the small number of cases in this category. 137 
Interactions were tested by including cross-product terms in the Cox models and performing Wald tests. 138 
To check for potential reversed causation, we excluded the first two years of follow-up. Secondly, we divided 139 
the total follow-up duration in two-year periods and compared the median baseline nut and peanut butter intake 140 
of cases diagnosed during these periods, using a Kruskal-Wallis test. Moreover, we restricted the analysis of 141 
peanut butter to participants who had stated having had a constant peanut butter intake in the five years 142 
preceding baseline. These data were not available for tree nut or peanut intake. In another sensitivity analyses, 143 
we adjusted for consumption of fruits, vegetables, dairy and cheese, and red and processed meat instead of the 144 
aMED score excluding alcohol and nuts. Furthermore, associations of tree nut, peanut, and peanut butter intake 145 
with endometrial and ovarian cancer were mutually adjusted. 146 
Analyses were performed with Stata 15 software (StataCorp. 2017. College Station, TX). P-values were tested 147 
two-sided and were considered statistically significant if <0.05.   148 
Results 149 
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In the analyses of endometrial cancer, mean (SD) total nut intake was slightly higher in cases (4.4 (8.6) g/day) 150 
than in the subcohort (4.2 (7.8) g/day) (Table 1). In the ovarian cancer analyses, mean (SD) total nut intake was 151 
4.2 (8.4) g/day among cases and 4.4 (8.6) g/day among subcohort members. Average intakes of tree nuts, 152 
peanuts, and peanut butter were almost similar in subcohort members and endometrial and ovarian cancer cases. 153 
Regarding other baseline characteristics, both endometrial and ovarian cancer cases were on average less 154 
physically active and less often ever cigarette smokers, parous, or oral contraceptive users than subcohort 155 
members. Moreover, endometrial and ovarian cancer cases had a later mean age at menopause and scored lower 156 
on the aMED score excluding alcohol and nuts (Table 1). Furthermore, compared to subcohort members, 157 
endometrial cancer cases were on average heavier, lower educated, reported a positive family history of 158 
endometrial cancer more often, had a lower age at menarche, and used hormone replacement therapy more often. 159 
Ovarian cancer cases more often reported a positive family history of ovarian cancer than subcohort members, 160 
but less often a positive family history of breast cancer, and they used hormone replacement therapy less often. 161 
Age- and multivariable-adjusted associations between nut and peanut butter intake and endometrial and ovarian 162 
cancer risk are presented in Table 2. In the age-adjusted analyses, no statistically significant relation of total nut 163 
intake was found with endometrial or ovarian cancer risk (HR (95% CI) for 10+ g/day vs. nonconsumers = 1.03 164 
(0.71-1.49), p-trend = 0.743, and 0.83 (0.57-1.20), p-trend = 0.305, respectively). Tree nut, peanut, and peanut 165 
butter consumption were also not significantly related to endometrial or ovarian cancer risk in age-adjusted 166 
analyses. After multivariable-adjustment, the nonsignificant positive associations between total nut and peanut 167 
intake and endometrial cancer risk became somewhat stronger, whereas the nonsignificant inverse associations 168 
between tree nut and peanut butter intake and endometrial cancer risk attenuated or became positive. For ovarian 169 
cancer, multivariable-adjustment did not change the results importantly. Total nut intake was not significantly 170 
associated with endometrial or ovarian cancer risk after multivariable-adjustment (HR (95% CI) for 10+ g/day 171 
vs. nonconsumers = 1.23 (0.82-1.87), p-trend = 0.449, and 0.84 (0.57-1.24), p-trend = 0.452, respectively). Also 172 
no significant relations with endometrial or ovarian cancer were observed for tree nut, peanut, and peanut butter 173 
intake. In continuous analyses, nut and peanut butter consumption were also not related to the risk of endometrial 174 
or ovarian cancer. 175 
In restricted cubic spline analyses with three fixed knots at 0, 5, and 10 g nut intake/day, no statistical evidence 176 
for nonlinear relations with endometrial or ovarian cancer risk were observed for all four exposure variables 177 
(Figure 2). However, the tests for nonlinearity were borderline significant for the relations between peanut butter 178 
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intake and endometrial cancer risk (p-nonlinearity = 0.062) and between total nut intake and ovarian cancer risk 179 
(p-nonlinearity = 0.081). When using additional knots or different knot positions, the model fit, as measured with 180 
the AIC score, did not improve importantly (data not shown). 181 
Table 3 and Supplementary Table 1 present the associations between total nut intake and endometrial and 182 
ovarian cancer risk in strata of potential effect modifiers. In the analyses of endometrial cancer stratified by BMI, 183 
no significant association between total nut intake and endometrial cancer risk was observed in participants with 184 
a BMI of 18.5-<25 kg/m2 (Table 3). A nonsignificant positive trend was observed in participants with a BMI ≥25 185 
kg/m2, with a significantly increased risk in the category of 0.1-<5 g total nut intake/day compared to 186 
nonconsumers (HR (95% CI) = 1.68 (1.13-2.48)). The test for interaction by BMI was significant (p-interaction 187 
= 0.016). For cigarette smoking status, no relation between total nut intake and endometrial cancer risk was 188 
found in never smokers, a nonsignificant positive association in former smokers, and a significant positive trend 189 
in current smokers (HR (95% CI) for 5+ g/day vs nonconsumers = 3.49 (1.25-9.73), p-trend = 0.021). The p-190 
interaction by smoking status was 0.019. In Figure 3, we further investigated the joint effects of total nut intake 191 
and cigarette smoking status on endometrial cancer risk, with never smokers who consumed 0 g total nuts/day as 192 
reference category. Increasing nut intake attenuated the inverse association between former cigarette smoking 193 
and endometrial cancer risk, and in women who consumed 5+ g total nuts/day, current smoking was even 194 
associated with a non-significantly increased endometrial cancer risk. In never smokers, no significant relation 195 
between nut intake and endometrial cancer was observed. Nevertheless, only currently smoking nonconsumers 196 
had a significantly lower endometrial cancer risk than never smoking nonconsumers (HR (95% CI) = 0.45 (0.25-197 
0.81)). For ovarian cancer, no significant interactions between total nut intake and potential effect modifiers 198 
were observed (Supplementary Table 1). 199 
No significant differences were found in the median baseline nut and peanut butter intake of endometrial and 200 
ovarian cancer cases diagnosed over the follow-up period in Kruskal-Wallis tests (p ≥0.206) (data not shown). 201 
Exclusion of the first two years of follow-up resulted in similar results as when the total follow-up period was 202 
included (data not shown). Moreover, restricting the analyses of the relation between peanut butter intake and 203 
endometrial and ovarian cancer risk to those participants who had stated having had a constant peanut butter 204 
intake in the five years before baseline also did not importantly change the results (data not shown).  205 
In another sensitivity analysis, adjustment for intake of fruits, vegetables, dairy and cheese, and red and 206 
processed meat gave similar estimates as when adjusting for the aMED score excluding nuts and alcohol (data 207 
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not shown). Moreover, mutually adjusting intake of tree nuts, peanuts, and peanut butter in relation to 208 
endometrial and ovarian cancer risk also did not change the results (data not shown). 209 
Discussion 210 
In the current study, total nut intake was not significantly related to the risk of endometrial or ovarian cancer. 211 
Similar results were found for tree nut, peanut, and peanut butter intake. For the relation between total nuts and 212 
endometrial cancer risk, we observed significant interactions by BMI and cigarette smoking status. 213 
Our results for ovarian cancer are in line with the results from the Swedish Women’s Lifestyle and Health 214 
Cohort Study [24], in which also no statistically significant association between nut consumption and ovarian 215 
cancer risk was observed. To our knowledge, this is the only other prospective cohort study investigating the 216 
relation between nut intake and ovarian cancer risk. No other prospective evidence is available for endometrial 217 
cancer.  218 
Besides the abovementioned cohort study, only two case-control studies have been performed on this topic for 219 
ovarian cancer [25, 26], and three case-control studies for endometrial cancer [21-23]. Regarding ovarian cancer, 220 
a Canadian case-control study did not find a relation between nut product intake frequency and ovarian cancer 221 
risk [26], and in an Australian case-control study, intake of omega-6 fatty acids from nuts was significantly 222 
associated with a reduced risk of epithelial ovarian cancer [25]. Because the relation of omega-6 fatty acids with 223 
ovarian cancer risk varied between the food sources of the omega-6 fatty acids, the authors stated that the 224 
estimates probably reflect a relation with nuts rather than with omega-6 fatty acids [25].  225 
Regarding endometrial cancer, one case-control study in Greece observed significant positive associations for 226 
intake of pulses and nuts combined [23], whereas a later Greek case-control study found a significant inverse 227 
association for pulse, nut, and seed consumption together [21]. In a Japanese case-control study, consuming 228 
peanuts ≥1-2x/week was associated with a significantly reduced risk of endometrial endometrioid carcinoma 229 
[22]. A borderline significant inverse trend was seen when peanut intake was expressed as intake density (g/1000 230 
kcal) [22]. Case-control studies are prone to selection and information biases, which may explain the 231 
contradictive results for both endometrial and ovarian cancer. Furthermore, none of the above-mentioned studies 232 
investigated the interaction between nut intake and cigarette smoking. Thus, the evidence on the relation between 233 
nut intake and endometrial and ovarian cancer is very limited, and further (prospective) research is required to 234 
confirm our results. 235 
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For endometrial cancer, we observed significant interactions of total nut intake with BMI. However, only the 236 
category of 0.1-<5 g total nut intake/day was significantly associated with an increased endometrial cancer risk 237 
in participants with a BMI higher than 25 kg/m2, and no significant exposure-response trends were observed in 238 
both BMI strata. Because of the number of significance tests performed, this finding may be due to chance. Nuts 239 
are energy-dense foods, and therefore concerns have been raised about weight gain resulting from increased nut 240 
intake. In case of hormone-dependent cancers, like endometrial and ovarian cancer, this is especially important 241 
because of the hormonal activity of adipose tissue [3, 35, 36]. However, several cross-sectional and prospective 242 
studies have indicated that higher nut intake is actually associated with reduced weight gain and a lower risk of 243 
becoming overweight or obese [37-40].  244 
The interaction between total nut intake and cigarette smoking in relation to endometrial cancer risk was also 245 
significant. In contrast to most cancer sites, cigarette smoking has been associated with a lower risk of 246 
endometrial cancer, particularly among postmenopausal women [41, 42]. This protective effect is hypothesized 247 
to be related to a reduction in the level of circulating unopposed estrogens: smoking has been found to modify 248 
the production and metabolism of estrogens, androgens, and progesterone, and to reduce body weight [41-43]. 249 
Moreover, smoking might have direct cytotoxic effects on the ovaries, which causes oocyte destruction and 250 
induces earlier menopause [42, 43]. In our study, increasing total nut intake appeared to counteract the protective 251 
effect of smoking (Figure 3), and even a non-significantly increased endometrial cancer risk was found in current 252 
smokers who consumed at least 5 g nuts/day. One possible explanation for this observation is that 253 
phytoestrogens in nuts might have estrogenic activity if the circulating concentration of unopposed endogenous 254 
estrogens is low [17, 44], which possibly counteracts the protective antiestrogenic effects of smoking. Nuts also 255 
contain several components with antioxidant, anti-inflammatory, and cell metabolism-modifying properties [16, 256 
19], which might also potentially oppose the effects of smoking. However, this is the first study investigating the 257 
interaction between nut intake and cigarette smoking in relation to endometrial cancer risk, and this finding 258 
needs to be confirmed in other studies first.  259 
Our study has some limitations. Only baseline measurements were performed, while dietary intakes may have 260 
changed over the 20.3 year follow-up period. Nevertheless, dietary habits appeared to be quite stable for at least 261 
five years in a reproducibility study [45]. Potential measurement error might have resulted in misclassification 262 
and thus in an attenuation of the results. Moreover, potential residual confounding by measured and unmeasured 263 
confounders cannot be excluded. For example, we had no information on risk factors like breastfeeding and tubal 264 
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ligation. Because these factors are unlikely to be associated with nut intake, they are not expected to confound 265 
our results. 266 
Strengths of the study are the prospective nature and the long and complete follow-up, which make selection and 267 
information bias unlikely. The large number of participants allowed us to extensively correct for potential 268 
confounders. Moreover, we were able to distinguish between tree nut, peanut, and peanut butter intake.  269 
In conclusion, the results of this prospective cohort study suggest that total nut, tree nut, peanut, and peanut 270 
butter intake are not related to the risk of endometrial or ovarian cancer. The observed interactions of nut intake 271 
in relation to endometrial cancer risk, in particular with cigarette smoking, need confirmation in other studies. 272 
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Table 1. Baseline characteristics (mean (SD) or %) of subcohort members and endometrial and ovarian cancer 374 
cases in the Netherlands Cohort Study, 1986-2006 375 
 a The subcohort sizes of the endometrial and ovarian cancer analyses differ because of differences in the in- and 376 
exclusion criteria (Figure 1).377 
 Endometrial cancer  Ovarian cancer 
 Subcohorta  Cases  Subcohorta  Cases 
N 1,452 389  1,646 347 
Age (years) 61.4 (4.2) 61.4 (4.3)  61.3 (4.2) 61.5 (4.2) 
Never cigarette smoker (%) 58.9 66.8  58.4 64.6 
Body Mass Index (kg/m2) 25.0 (3.5) 26.4 (4.1)  25.0 (3.5) 25.1 (3.6) 
Non-occupational physical activity (min/day) 66.3 (51.0) 58.6 (46.3)  66.0 (50.4) 57.8 (37.5) 
University or higher vocational education (%) 9.7 8.7  9.7 9.5 
Family history of endometrial cancer (%) 2.8 4.4    
Family history of ovarian cancer (%)    0.1 0.6 
Family history of breast cancer (%)    8.7 7.8 
Age at menarche (years) 13.7 (1.8) 13.4 (1.6)  13.7 (1.8) 13.7 (1.8) 
Age at menopause (years) 49.1 (4.3) 50.2 (3.9)  48.9 (4.4) 49.3 (3.9) 
Parous (%) 81.2 73.5  81.8 76.1 
Age at first birth (in parous, years) 27.1 (4.2) 27.1 (3.9)  27.0 (4.2) 27.6 (4.1) 
Number of children (in parous, n) 3.4 (1.9) 3.1 (1.7)  3.4 (1.9) 3.2 (1.7) 
Ever used oral contraceptives (%) 24.5 13.9  25.3 19.0 
Ever used hormone replacement therapy (%) 11.8 16.5  13.4  12.4 
Daily energy intake (kcal) 1,687 (390) 1,658 (398)  1,688 (392) 1,695 (389) 
Total nut intake (g/day) 4.2 (7.8) 4.4 (8.6)  4.4 (8.6) 4.2 (8.4) 
Tree nut intake (g/day) 1.0 (2.7) 1.0 (3.0)  1.1 (4.1) 1.0 (2.9) 
Peanut intake (g/day) 3.3 (6.8) 3.4 (6.9)  3.3 (6.9) 3.2 (6.6) 
Peanut butter intake (g/day) 1.2 (3.6) 1.1 (3.2)  1.2 (3.5) 1.2 (3.7) 
aMED score (excl. alcohol and nuts) of 5-7 pts (%) 26.5 23.1  26.6 23.9 
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Table 2. Age- and multivariable-adjusted HRs (and 95% CIs) for endometrial and ovarian cancer according to nut consumption; NLCS, 1986-2006 378 
 Endometrial cancer  Ovarian cancer 
 Median 
intakea 
Person-
years 
Cases Age-adjusted  
HR (95% CI) 
Multivariable- 
adjusted HRb  
(95% CI) 
 Median 
intakea 
Person-
years 
Cases Age-adjusted  
HR (95% CI) 
Multivariable- 
adjusted HRb  
(95% CI) 
Total nuts (g/day)            
0 0.0 9,912 143 1.00 (reference) 1.00 (reference)  0.0 11,388 158 1.00 (reference) 1.00 (reference) 
0.1-<5 2.1 9,500 160 1.18 (0.91-1.53) 1.26 (0.94-1.67)  2.1 10,817 117 0.80 (0.61-1.04) 0.79 (0.59-1.05) 
5-<10 7.8 2,876 37 0.91 (0.60-1.38) 1.21 (0.76-1.92)  7.8 3,115 28 0.68 (0.43-1.06) 0.71 (0.45-1.14) 
10+ 15.5 3,338 49 1.03 (0.71-1.49) 1.23 (0.82-1.87)  15.7 3,919 44 0.83 (0.57-1.20) 0.84 (0.57-1.24) 
Ptrend    0.743 0.449     0.305 0.425 
Continuous, per 5 
g/day increment 
   1.01 (0.93-1.08) 1.06 (0.97-1.14)     0.98 (0.91-1.06) 0.99 (0.91-1.07) 
            
Tree nuts (g/day)            
0 0.0 17,973 277 1.00 (reference) 1.00 (reference)  0.0 20,505 248 1.00 (reference) 1.00 (reference) 
0.1-<5 1.6 6,204 93 0.98 (0.75-1.27) 1.03 (0.76-1.39)  1.6 7,008 85 1.02 (0.78-1.33) 1.04 (0.77-1.41) 
5+ 8.9 1,450 19 0.85 (0.51-1.43) 1.08 (0.62-1.90)  8.9 1,727 14 0.69 (0.38-1.23) 0.71 (0.39-1.32) 
Ptrend    0.543 0.767     0.226 0.317 
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Continuous, per 5 
g/day increment 
   0.99 (0.78-1.25) 1.06 (0.83-1.36)     0.94 (0.80-1.12) 0.96 (0.82-1.13) 
            
Peanuts (g/day)            
0 0.0 11,772 175 1.00 (reference) 1.00 (reference)  0.0 13,535 182 1.00 (reference) 1.00 (reference) 
0.1-<5 2.1 9,548 151 1.08 (0.84-1.39) 1.20 (0.91-1.57)  2.0 10,791 111 0.78 (0.60-1.02) 0.81 (0.61-1.06) 
5-<10 8.5 2,063 31 1.03 (0.66-1.61) 1.19 (0.73-1.96)  8.5 2,249 21 0.73 (0.44-1.19) 0.75 (0.45-1.26) 
10+ 14.4 2,242 32 0.97 (0.63-1.49) 1.16 (0.73-1.85)  17.1 2,666 33 0.94 (0.63-1.43) 0.96 (0.62-1.47) 
Ptrend    0.896 0.499     0.699 0.792 
Continuous, per 5 
g/day increment 
   1.01 (0.93-1.09) 1.06 (0.98-1.16)     0.99 (0.90-1.08) 1.00 (0.91-1.10) 
            
Peanut butter (g/day)            
0 0.0 18,388 298 1.00 (reference) 1.00 (reference)  0.0 21,173 257 1.00 (reference) 1.00 (reference) 
0.1-<5 1.2 4,654 58 0.77 (0.57-1.06) 0.83 (0.59-1.17)  1.2 5,275 55 0.87 (0.63-1.20) 0.88 (0.63-1.21) 
5+ 5.3 2,584 33 0.79 (0.53-1.18) 0.84 (0.54-1.30)  5.3 2,792 35 1.05 (0.71-1.56) 1.02 (0.67-1.54) 
Ptrend    0.186 0.359     0.896 0.989 
Continuous, per 5 
g/day increment 
   0.92 (0.77-1.11) 0.96 (0.79-1.17)     1.02 (0.85-1.22) 1.00 (0.83-1.21) 
a Median intake in the female subcohort. 379 
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b Adjusted for age (years; continuous), cigarette smoking (status (never, former, current), frequency (n/day; continuous, centered), and duration (years; continuous, centered)), 380 
BMI (<18.5, 18.5-<25, 25-<30, ≥30 kg/m2), nonoccupational physical activity (≤30, >30-60, >60-90, >90 min/day), educational level (low, medium, high), family history of 381 
endometrial cancer (no, yes; in the endometrial cancer analysis only), family history of breast cancer (no, yes; in the ovarian cancer analysis only), age at menarche (years; 382 
continuous), age at menopause (years; continuous), parity and age at first child birth (nulliparous, 1-2 children - <25 years, 1-2 children - ≥25 years, ≥3 children - <25 years, 383 
≥3 children - ≥25 years), oral contraceptive use (never, ever), hormone replacement therapy use (never, ever), daily energy intake (kcal/day; continuous), alternate 384 
Mediterranean diet score excluding alcohol and nuts (0-2, 3-4, 5-7 points).  385 
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Table 3. Multivariable-adjusted associations between total nut intake and endometrial cancer risk in strata of 386 
potential effect modifiers; NLCS, 1986-2006 387 
 Total nut consumption (g/day)  
Ptrend Pinteraction 
 0 g/day 0.1-<5 g/day 5+ g/day 
Endometrial cancer       
Overall      
Cases/person-time at risk (years) 143/9,912 160/9,500 86/6,214   
HR (95% CI)a 1.00 (reference) 1.26 (0.94-1.67) 1.22 (0.86-1.74) 0.410  
      
Body mass indexb      
18.5-<25 kg/m2      
Cases/person-time at risk (years) 65/4,959 51/5,085 48/4,121   
HR (95% CI)a 1.00 (reference) 0.76 (0.49-1.18) 1.07 (0.65-1.77) 0.512 0.016 
25+ kg/m2      
Cases/person-time at risk (years) 76/4,768 108/4,343 38/2,033   
HR (95% CI)a 1.00 (reference) 1.68 (1.13-2.48) 1.24 (0.73-2.09) 0.775  
      
Nonoccupational physical activity      
≤30 min/day      
Cases/person-time at risk (years) 46/2,650 44/1,752 23/1,073   
HR (95% CI)a 1.00 (reference) 1.44 (0.83-2.50) 1.24 (0.56-2.73) 0.689 0.650 
>30-≤60 min/day      
Cases/person-time at risk (years) 36/3,029 56/3,121 33/2,109   
HR (95% CI)a 1.00 (reference) 1.74 (1.01-3.00) 1.61 (0.83-3.12) 0.341  
>60-≤90 min/day      
Cases/person-time at risk (years) 31/2,153 32/2,392 13/1,447   
HR (95% CI)a 1.00 (reference) 0.93 (0.45-1.91) 0.84 (0.36-1.94) 0.682  
>90 min/day      
Cases/person-time at risk (years) 30/2,080 28/2,235 17/1,585   
HR (95% CI)a 1.00 (reference) 0.97 (0.40-2.33) 0.96 (0.36-2.54) 0.937  
      
Cigarette smoking status      
Never      
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Cases/person-time at risk (years) 106/6,166 114/5,791 40/3,320   
HR (95% CI)a 1.00 (reference) 1.21 (0.86-1.71) 0.83 (0.51-1.35) 0.322 0.019 
Former      
Cases/person-time at risk (years) 20/1,507 28/2,148 24/1,758   
HR (95% CI)a 1.00 (reference) 1.23 (0.55-2.78) 1.32 (0.56-3.07) 0.594  
Current      
Cases/person-time at risk (years) 17/2,239 18/1,562 22/1,137   
HR (95% CI)a 1.00 (reference) 1.97 (0.78-4.94) 3.49 (1.25-9.73) 0.021  
      
Educational level      
Low      
Cases/person-time at risk (years) 84/6,013 92/4,941 37/2,673   
HR (95% CI)a 1.00 (reference) 1.50 (1.02-2.21) 1.32 (0.79-2.21) 0.397 0.620 
Medium      
Cases/person-time at risk (years) 49/3,316 54/3,507 39/2,696   
HR (95% CI)a 1.00 (reference) 1.05 (0.62-1.77) 1.11 (0.59-2.09) 0.752  
High      
Cases/person-time at risk (years) 10/583 14/1,052 10/845   
HR (95% CI)a 1.00 (reference) 0.84 (0.14-5.16) 0.64 (0.10-4.05) 0.576  
      
Adapted Mediterranean diet score excluding 
nuts and alcohol 
     
0-2 points      
Cases/person-time at risk (years) 35/2,980 50/2,088 17/1,372   
HR (95% CI)a 1.00 (reference) 2.22 (1.15-4.28) 1.27 (0.54-2.99) 0.883 0.169 
3-4 points      
Cases/person-time at risk (years) 79/4,855 74/4,596 44/2,875   
HR (95% CI)a 1.00 (reference) 1.04 (0.69-1.57) 1.23 (0.74-2.05) 0.424  
5-7 points      
Cases/person-time at risk (years) 29/2,077 36/2,817 25/1,967   
HR (95% CI)a 1.00 (reference) 0.87 (0.43-1.74) 1.05 (0.48-2.28) 0.720  
a Adjusted for age (years; continuous), cigarette smoking (status (never, former, current), frequency (n/day; 388 
continuous, centered), and duration (years; continuous, centered)), BMI (<18.5, 18.5-<25, 25-<30, ≥30 kg/m2), 389 
nonoccupational physical activity (≤30, >30-60, >60-90, >90 min/day), educational level (low, medium, high), 390 
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family history of endometrial cancer (no, yes), age at menarche (years; continuous), age at menopause (years; 391 
continuous), parity and age at first child birth (nulliparous, 1-2 children - <25 years, 1-2 children - ≥25 years, ≥3 392 
children - <25 years, ≥3 children - ≥25 years), oral contraceptive use (never, ever), hormone replacement therapy 393 
use (never, ever), daily energy intake (kcal/day; continuous), alternate Mediterranean diet score excluding 394 
alcohol and nuts (0-2, 3-4, 5-7 points). 395 
b Participants with a BMI <18.5 kg/m2 (n = 22) were excluded from the interaction analysis.  396 
  397 
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 405 
 406 
Figure 1. Flow chart of the number of subcohort members and ovarian and endometrial cancer cases; the NLCS, 407 
1986-2006 408 
a Hysterectomy excluded from the analysis of endometrial cancer, oophorectomy excluded from the analysis of 409 
ovarian cancer 410 
  411 
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 Figure 2. Restricted cubic spline analyses with three fixed knots at 0, 5, and 10 g intake/day, investigating the 412 
relation between nut and peanut butter consumption and the risk of endometrial and ovarian cancer. Solid lines 413 
represent HRs, dashed lines 95% confidence limits. P-values for nonlinearity for total nut, tree nut, peanut, and 414 
peanut butter intake were 0.724, 0.558, 0.640, and 0.062 for endometrial cancer, and 0.081, 0.911, 0.283, and 415 
0.492 for ovarian cancer, respectively. Results were adjusted for age (years; continuous), cigarette smoking 416 
(status (never, former, current), frequency (n/day; continuous, centered), and duration (years; continuous, 417 
centered)), BMI (<18.5, 18.5-<25, 25-<30, ≥30 kg/m2), nonoccupational physical activity (≤30, >30-60, >60-90, 418 
>90 min/day), educational level (low, medium, high), family history of endometrial cancer (no, yes; in the 419 
endometrial cancer analyses only), family history of breast cancer (no, yes; in the ovarian cancer analyses only), 420 
age at menarche (years; continuous), age at menopause (years; continuous), parity and age at first child birth 421 
(nulliparous, 1-2 children - <25 years, 1-2 children - ≥25 years, ≥3 children - <25 years, ≥3 children - ≥25 years), 422 
oral contraceptive use (never, ever), hormone replacement therapy use (never, ever), daily energy intake 423 
(kcal/day; continuous), alternate Mediterranean diet score excluding alcohol and nuts (0-2, 3-4, 5-7 points) 424 
  425 
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 433 
 434 
Figure 3. Combined exposure to total nuts and cigarette smoking and the risk of endometrial cancer; the NLCS, 435 
1986-2006. Never cigarette smokers who consumed 0 g nuts/day are the reference category. Results were 436 
adjusted for age (years; continuous), cigarette smoking (frequency (n/day; continuous, centered) and duration 437 
(years; continuous, centered)), BMI (<18.5, 18.5-<25, 25-<30, ≥30 kg/m2); nonoccupational physical activity 438 
(≤30, >30-60, >60-90, >90 min/day), educational level (low, medium, high), family history of endometrial 439 
cancer (no, yes), age at menarche (years; continuous), age at menopause (years; continuous), parity and age at 440 
first child birth (nulliparous, 1-2 children - <25 years, 1-2 children - ≥25 years, ≥3 children - <25 years, ≥3 441 
children - ≥25 years), oral contraceptive use (never, ever), hormone replacement therapy use (never, ever), daily 442 
energy intake (kcal/day; continuous), alternate Mediterranean diet score excluding alcohol and nuts (0-2, 3-4, 5-7 443 
points) 444 
* indicates a significant association (p<0.05)  445 
  446 
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Supplementary Table 1. Multivariable-adjusted associations between total nut intake and ovarian 447 
cancer risk in strata of potential effect modifiers; NLCS, 1986-2006 448 
 Total nut consumption (g/day)  
Ptrend Pinteraction 
 0 g/day 0.1-<5 g/day 5+ g/day 
Ovarian cancer      
Overall      
Cases/person-time at risk (years) 158/11,388 117/10,817 72/7,034   
HR (95% CI)a 1.00 (reference) 0.79 (0.60-1.05) 0.78 (0.56-1.10) 0.258  
      
Body mass indexb      
18.5-<25 kg/m2      
Cases/person-time at risk (years) 78/5,765 65/5,651 38/4,666   
HR (95% CI)a 1.00 (reference) 0.96 (0.65-1.42) 0.71 (0.45-1.13) 0.135 0.194 
25+ kg/m2      
Cases/person-time at risk (years) 80/5,389 51/5,095 32/2,309   
HR (95% CI)a 1.00 (reference) 0.61 (0.39-0.95) 0.85 (0.50-1.46) 0.869  
      
Nonoccupational physical activity      
≤30 min/day      
Cases/person-time at risk (years) 44/2,942 24/2,033 17/1,287   
HR (95% CI)a 1.00 (reference) 0.73 (0.38-1.38) 0.77 (0.37-1.57) 0.534 0.718 
>30-≤60 min/day      
Cases/person-time at risk (years) 56/3,411 46/3,580 21/2,418   
HR (95% CI)a 1.00 (reference) 0.77 (0.47-1.26) 0.59 (0.32-1.10) 0.125  
>60-≤90 min/day      
Cases/person-time at risk (years) 34/2,633 27/2,720 22/1,657   
HR (95% CI)a 1.00 (reference) 0.69 (0.36-1.32) 0.95 (0.47-1.93) 0.827  
>90 min/day      
Cases/person-time at risk (years) 24/2,403 20/2,485 12/1,672   
HR (95% CI)a 1.00 (reference) 0.89 (0.42-1.91) 0.85 (0.35-2.06) 0.743  
      
Cigarette smoking status      
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Never      
Cases/person-time at risk (years) 103/7,077 82/6,612 39/3,677   
HR (95% CI)a 1.00 (reference) 0.84 (0.59-1.19) 0.73 (0.47-1.13) 0.193 0.399 
Former      
Cases/person-time at risk (years) 27/1,744 19/2,444 17/2,008   
HR (95% CI)a 1.00 (reference) 0.47 (0.22-0.99) 0.48 (0.21-1.08) 0.219  
Current      
Cases/person-time at risk (years) 28/2,567 16/1,761 16/1,349   
HR (95% CI)a 1.00 (reference) 0.94 (0.44-1.99) 1.53 (0.66-3.51) 0.283  
      
Educational level      
Low      
Cases/person-time at risk (years) 87/6,909 60/5,730 41/3,156   
HR (95% CI)a 1.00 (reference) 0.85 (0.58-1.26) 1.08 (0.67-1.73) 0.654 0.304 
Medium      
Cases/person-time at risk (years) 60/3,780 43/3,904 23/2,933   
HR (95% CI)a 1.00 (reference) 0.62 (0.38-0.99) 0.47 (0.26-0.85) 0.031  
High      
Cases/person-time at risk (years) 11/669 14/1,183 8/946   
HR (95% CI)a 1.00 (reference) 2.38 (0.39-14.46) 0.92 (0.18-4.57) 0.583  
      
Family history of breast cancer      
No      
Cases/person-time at risk (years) 147/10,472 107/9,679 66/6,527   
HR (95% CI)a 1.00 (reference) 0.81 (0.60-1.10) 0.79 (0.56-1.12) 0.267 0.699 
Yes      
Cases/person-time at risk (years) 11/916 10/1,138 6/507   
HR (95% CI)a 1.00 (reference) 0.53 (0.13-2.18) 0.83 (0.18-3.75) 0.960  
      
Adapted Mediterranean diet score excluding 
nuts and alcohol 
     
0-2 points      
Cases/person-time at risk (years) 41/3,362 37/2,430 15/1,506   
28 
 
HR (95% CI)a 1.00 (reference) 1.36 (0.71-2.61) 0.75 (0.36-1.55) 0.299 0.165 
3-4 points      
Cases/person-time at risk (years) 82/5,625 56/5,199 33/3,306   
HR (95% CI)a 1.00 (reference) 0.72 (0.48-1.08) 0.72 (0.44-1.18) 0.286  
5-7 points      
Cases/person-time at risk (years) 35/2,401 24/3,188 24/2,223   
HR (95% CI)a 1.00 (reference) 0.55 (0.29-1.04) 0.98 (0.47-2.01) 0.620  
a Adjusted for age (years; continuous), cigarette smoking (status (never, former, current), frequency (n/day; 449 
continuous, centered), and duration (years; continuous, centered)), BMI (<18.5, 18.5-<25, 25-<30, ≥30 kg/m2), 450 
nonoccupational physical activity (≤30, >30-60, >60-90, >90 min/day), educational level (low, medium, high), 451 
family history of breast cancer (no, yes), age at menarche (years; continuous), age at menopause (years; 452 
continuous), parity and age at first child birth (nulliparous, 1-2 children - <25 years, 1-2 children - ≥25 years, ≥3 453 
children - <25 years, ≥3 children - ≥25 years), oral contraceptive use (never, ever), hormone replacement therapy 454 
use (never, ever), daily energy intake (kcal/day; continuous), alternate Mediterranean diet score excluding 455 
alcohol and nuts (0-2, 3-4, 5-7 points). 456 
b Participants with a BMI <18.5 kg/m2 (n = 25) were excluded from the interaction analysis. 457 
